Breyanzi (lisocabtagene maraleucel) - BMS
Imbruvica (ibrutinib) - AbbVie, J&J
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
cyclophosphamide - Generic mfg.
fludarabine IV - Generic mfg.
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov) - Oct 2, 2026 - P2 | N=9 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Sep 2026 ➔ Aug 2027 | Trial primary completion date: Sep 2026 ➔ Aug 2027 
Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Richter's Syndrome
http://clinicaltrials.gov/ct2/show/NCT05672173
 
Oct 2, 2026
 
Prev Next